It is indeed difficult for some patients (particularly in early stages when symptoms are mild and self-manageable) to accept the necessity of a chronic treatment.
However, IPF is a relentlessly progressive disease. There are encouraging data regarding the efficacy of both pirfenidone and nintedanib in IPF patients with preserved lung volumes. The above findings actually coincide with common sense. It is reasonable that early intervention preserves more functional lung parenchyma and reduces the possibility of an acute exacerbation occuring on a severely fibrotic lung.
For further reading:
- Kolb M et al. Am J Respir Crit Care Med 191;2015:A1021.
- Raghu G et al. Am J Respir Crit Care Med 191;2015:A1022.
- Albera C et al. Am J Respir Crit Care Med 191;2015:A1018.